Technology

DOJ staff are reported to be planning a second request for additional information in the antitrust review of Fox's $22 billion acquisition of Roku, a step that would extend the review timeline beyond its initial phase and could pressure the deal's targeted first-half 2027 close. As of September 9, 2026, no formal DOJ confirmation or SEC filing has documented the request's issuance; the report rests on unnamed sources cited by Semafor, with Reuters noting it could not independently verify the information. Regulatory concerns center on whether a combined Fox-Roku entity could favor Fox programming on Roku's connected-TV platform, which reaches more than 100 million households globally.

Apple has officially scheduled its 'Surprise and Shine' event for September 9 at 10 a.m. PT, viewable at apple.com and via the Apple TV app, but has not confirmed any product announcements, specifications, pricing, or release dates ahead of the presentation. The event also follows Apple's leadership transition, with John Ternus having become CEO on September 1, 2026, succeeding Tim Cook who moved to executive chairman. Specific products widely anticipated by analysts, including iPhone 18 Pro models and a foldable iPhone, remain unconfirmed until Apple speaks.

Holtec Nuclear Corporation launched an IPO roadshow on September 8, 2026, proposing to sell 50 million Class A shares at $15 to $18 each, with gross proceeds of up to $900 million and a fully exchanged equity valuation of up to $10.2 billion on Nasdaq. The registration statement remains preliminary and not yet effective, meaning no shares can be sold and no final price has been set. The company's two flagship projects, the Palisades plant restart and the Pioneer SMR-300 small modular reactors, each carry substantial outstanding regulatory requirements that are separate from company timelines and existing government financing commitments.

Windward Bio announced on September 8, 2026, that its anti-TSLP antibody WIN378 had advanced to Phase 3 in the POLARIS-1 asthma study, citing interim Phase 2 data showing placebo-adjusted FEV₁ gains of up to 256 mL and a 51% drop in blood eosinophils. However, the corresponding ClinicalTrials.gov record still classifies the study as Phase 2 with a 136-participant target, and no separate Phase 3 registration was found in the registry. The discrepancy means the Phase 3 initiation cannot be independently verified through public trial records, and the interim efficacy figures remain company-reported and unreviewed by regulators or peer reviewers.